436 related articles for article (PubMed ID: 28646122)
1. Nintedanib, a triple tyrosine kinase inhibitor, attenuates renal fibrosis in chronic kidney disease.
Liu F; Wang L; Qi H; Wang J; Wang Y; Jiang W; Xu L; Liu N; Zhuang S
Clin Sci (Lond); 2017 Aug; 131(16):2125-2143. PubMed ID: 28646122
[TBL] [Abstract][Full Text] [Related]
2. Synergistic Inhibition of Renal Fibrosis by Nintedanib and Gefitinib in a Murine Model of Obstructive Nephropathy.
Feng L; Li W; Chao Y; Huan Q; Lu F; Yi W; Jun W; Binbin C; Na L; Shougang Z
Kidney Dis (Basel); 2021 Jan; 7(1):34-49. PubMed ID: 33614732
[TBL] [Abstract][Full Text] [Related]
3. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
Wollin L; Maillet I; Quesniaux V; Holweg A; Ryffel B
J Pharmacol Exp Ther; 2014 May; 349(2):209-20. PubMed ID: 24556663
[TBL] [Abstract][Full Text] [Related]
4. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.
Hostettler KE; Zhong J; Papakonstantinou E; Karakiulakis G; Tamm M; Seidel P; Sun Q; Mandal J; Lardinois D; Lambers C; Roth M
Respir Res; 2014 Dec; 15(1):157. PubMed ID: 25496490
[TBL] [Abstract][Full Text] [Related]
5. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
Huang J; Beyer C; Palumbo-Zerr K; Zhang Y; Ramming A; Distler A; Gelse K; Distler O; Schett G; Wollin L; Distler JH
Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
[TBL] [Abstract][Full Text] [Related]
6. Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway.
Kamio K; Usuki J; Azuma A; Matsuda K; Ishii T; Inomata M; Hayashi H; Kokuho N; Fujita K; Saito Y; Miya T; Gemma A
Pulm Pharmacol Ther; 2015 Jun; 32():29-36. PubMed ID: 25843005
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of spleen tyrosine kinase (syk) suppresses renal fibrosis through anti-inflammatory effects and down regulation of the MAPK-p38 pathway.
Chen KH; Hsu HH; Yang HY; Tian YC; Ko YC; Yang CW; Hung CC
Int J Biochem Cell Biol; 2016 May; 74():135-44. PubMed ID: 26948651
[TBL] [Abstract][Full Text] [Related]
8. A role for spleen tyrosine kinase in renal fibrosis in the mouse obstructed kidney.
Ma FY; Blease K; Nikolic-Paterson DJ
Life Sci; 2016 Feb; 146():192-200. PubMed ID: 26779657
[TBL] [Abstract][Full Text] [Related]
9. Induction of renal fibrotic genes by TGF-β1 requires EGFR activation, p53 and reactive oxygen species.
Samarakoon R; Dobberfuhl AD; Cooley C; Overstreet JM; Patel S; Goldschmeding R; Meldrum KK; Higgins PJ
Cell Signal; 2013 Nov; 25(11):2198-209. PubMed ID: 23872073
[TBL] [Abstract][Full Text] [Related]
10. A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy.
Pang M; Ma L; Gong R; Tolbert E; Mao H; Ponnusamy M; Chin YE; Yan H; Dworkin LD; Zhuang S
Kidney Int; 2010 Aug; 78(3):257-68. PubMed ID: 20520592
[TBL] [Abstract][Full Text] [Related]
11. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis.
Huang J; Maier C; Zhang Y; Soare A; Dees C; Beyer C; Harre U; Chen CW; Distler O; Schett G; Wollin L; Distler JHW
Ann Rheum Dis; 2017 Nov; 76(11):1941-1948. PubMed ID: 28814429
[TBL] [Abstract][Full Text] [Related]
12. Src inhibition blocks renal interstitial fibroblast activation and ameliorates renal fibrosis.
Yan Y; Ma L; Zhou X; Ponnusamy M; Tang J; Zhuang MA; Tolbert E; Bayliss G; Bai J; Zhuang S
Kidney Int; 2016 Jan; 89(1):68-81. PubMed ID: 26444028
[TBL] [Abstract][Full Text] [Related]
13. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity.
Sato S; Shinohara S; Hayashi S; Morizumi S; Abe S; Okazaki H; Chen Y; Goto H; Aono Y; Ogawa H; Koyama K; Nishimura H; Kawano H; Toyoda Y; Uehara H; Nishioka Y
Respir Res; 2017 Sep; 18(1):172. PubMed ID: 28915889
[TBL] [Abstract][Full Text] [Related]
14. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Wollin L; Wex E; Pautsch A; Schnapp G; Hostettler KE; Stowasser S; Kolb M
Eur Respir J; 2015 May; 45(5):1434-45. PubMed ID: 25745043
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of tyrosine kinase receptor signaling attenuates fibrogenesis in an ex vivo model of human renal fibrosis.
Bigaeva E; Stribos EGD; Mutsaers HAM; Piersma B; Leliveld AM; de Jong IJ; Bank RA; Seelen MA; van Goor H; Wollin L; Olinga P; Boersema M
Am J Physiol Renal Physiol; 2020 Jan; 318(1):F117-F134. PubMed ID: 31736352
[TBL] [Abstract][Full Text] [Related]
16. Amygdalin inhibits renal fibrosis in chronic kidney disease.
Guo J; Wu W; Sheng M; Yang S; Tan J
Mol Med Rep; 2013 May; 7(5):1453-7. PubMed ID: 23525378
[TBL] [Abstract][Full Text] [Related]
17. RIG-I aggravates interstitial fibrosis via c-Myc-mediated fibroblast activation in UUO mice.
Zhou Z; Ni J; Li J; Huo C; Miao N; Yin F; Cheng Q; Xu D; Xie H; Chen P; Zheng P; Zhang Y; Zhou L; Zhang W; Yu C; Liu J; Lu L
J Mol Med (Berl); 2020 Apr; 98(4):527-540. PubMed ID: 32036390
[TBL] [Abstract][Full Text] [Related]
18. Pomolic Acid Ameliorates Fibroblast Activation and Renal Interstitial Fibrosis through Inhibition of SMAD-STAT Signaling Pathways.
Park JH; Jang KM; An HJ; Kim JY; Gwon MG; Gu H; Park B; Park KK
Molecules; 2018 Sep; 23(9):. PubMed ID: 30177595
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting aerobic glycolysis suppresses renal interstitial fibroblast activation and renal fibrosis.
Ding H; Jiang L; Xu J; Bai F; Zhou Y; Yuan Q; Luo J; Zen K; Yang J
Am J Physiol Renal Physiol; 2017 Sep; 313(3):F561-F575. PubMed ID: 28228400
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of fasudil on renal interstitial fibrosis induced by unilateral ureteral obstruction.
Baba I; Egi Y; Utsumi H; Kakimoto T; Suzuki K
Mol Med Rep; 2015 Dec; 12(6):8010-20. PubMed ID: 26498136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
